SPH3348 Tablets in a Single-center, Randomized, Open-label, Single-dose, Two-period, Two-sequence Crossover Design Food Effect Study in Healthy Chinese Subjects

The goal of this clinical trial is to evaluate the pharmacokinetic (PK) characteristics of single oral doses of SPH3348 tablets in healthy subjects under fasting and fed conditions, as well as the impact of food on PK.

Study Overview

• Status: Completed
• Conditions: Pharmacokinetics; Antitumor Drug
• Intervention / Treatment: Drug: SPH3348

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Chengdu, China
    • West China Second University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• To be eligible for this trial, participants must meet all the following inclusion criteria:

  1. Fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial, and sign an informed consent form, being able to complete all trial processes as required by the protocol;
  2. Be healthy adult males or females aged 18 to 45 years, inclusive of the boundary values;
  3. Have a body mass index (BMI) of 18 to 26 kg/m^2, inclusive of the boundary values, with a minimum weight of 50 kg for males and 45 kg for females;
  4. Participants with potential for fertility must use at least one medically recognized contraceptive method during the study treatment period and for one year after the end of the study treatment (contraceptive methods and requirements are detailed in Appendix 1); females must undergo a pregnancy test during the screening period or at admission, with a result that must be negative; and must not be breastfeeding.

Exclusion Criteria:

• Participants who meet any of the following exclusion criteria will be excluded:

  1. Have a history of clinically significant diseases in the heart, liver, kidney, respiratory, hematopoietic, nervous, urinary reproductive systems, or mental diseases, severe infections, severe trauma, or major surgical procedures within 3 months before administration, or plan to undergo surgical procedures during the study;
  2. Have a history of suspected allergy to the study drug or any component of the study drug (including drug allergies and food allergies, etc.);
  3. Have a history of diseases or have received treatments that affect the absorption, distribution, metabolism, and excretion of drugs in the body, as determined by the investigator, such as gastrectomy, gastrointestinal anastomosis, laparoscopic Roux-en-Y gastric bypass surgery, etc.;
  4. Have difficulty with venous blood collection or have a history of fainting from needles or blood or physical conditions that cannot withstand intensive blood collection;
  5. Have an average daily smoking consumption of more than 5 cigarettes in the 3 months before screening or are unable to give up the use of tobacco products during the entire trial period;
  6. Have a history of drug use, a history of drug abuse (such as THC, morphine, ketamine, methamphetamine, MDMA) within 6 months before screening, or have a positive urine drug screen;
  7. Consume more than 14 units of alcohol per week in the 6 months before screening (1 standard unit = 14 g of alcohol = 360 mL of beer or 45 mL of liquor with 40% alcohol or 150 mL of wine) or are unable to abstain from alcohol during the trial period, or have an abnormal alcohol breath test (acceptable range: 0~3 mg/100 mL);
  8. Have used any prescription drugs, over-the-counter drugs, Chinese herbal medicine, or health products within 4 weeks before the start of the trial;
  9. Be vegetarians, have dietary restrictions that cannot comply with a uniform diet, or have difficulty swallowing;
  10. Have consumed foods that affect liver enzymes (such as grapefruit and grapefruit-containing products) or any foods rich in xanthine substances (such as coffee, tea, chocolate, cocoa, milk tea, etc.) within 48 hours before taking medication, or have engaged in vigorous exercise;
  11. Test positive for Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibody (HCV-Ab), Human Immunodeficiency Virus antibody (HIV-Ab), or syphilis antibody;
  12. Have abnormal results in vital sign assessment, physical examination, laboratory tests, 12-lead ECG, and chest PA X-ray that are clinically significant;
  13. Have a corrected QT interval (QTcB) obtained from a 12-lead ECG at rest of >450 ms in males and >470 ms in females at screening, or have other abnormalities deemed clinically significant by the investigator;
  14. Have participated in other drug or medical device clinical trials within 3 months before screening;
  15. Have received or plan to receive live (attenuated) vaccines during the trial process or within one month after administration;
  16. Have donated blood or lost a total of ≥200 mL of blood within 1 month before screening, or have donated blood or lost ≥400 mL within 3 months before administration; have received blood transfusions or blood products;
  17. Are deemed ineligible for enrollment by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Single oral administration of SPH3348 tablets under fasting condition; Single oral administration of SPH3348 tablets（480 mg） under fasting condition	Drug: SPH3348; Single oral administration of SPH3348 tablets（480mg） under fasting and fed conditions
Active Comparator: Single oral administration of SPH3348 tablets under fed condition; Single oral administration of SPH3348 tablets（480 mg） under fed condition	Drug: SPH3348; Single oral administration of SPH3348 tablets（480mg） under fasting and fed conditions

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax	Peak Concentration	Cmax occurs within 1.5 to 4 hours after dosing
Tmax	"Time to Reach Maximum Concentration	From administration to reaching maximum plasma concentration, typically around 3 hours
AUC0-t		AUC0-t is measured from time 0 to 32 hours post-dose

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	through study completion, an average of 17 days

Collaborators and Investigators

• Sponsor: West China Second University Hospital
• Collaborators: Shanghai Pharmaceuticals Holding Co., Ltd
• Investigators: Principal Investigator: yu, National Drug Clinical Trial Institution of West China Second Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 15, 2022
• Primary Completion (Actual): August 14, 2022
• Study Completion (Actual): November 2, 2022

Study Registration Dates

• First Submitted: October 16, 2024
• First Submitted That Met QC Criteria: October 19, 2024
• First Posted (Actual): October 22, 2024

Study Record Updates

• Last Update Posted (Actual): October 22, 2024
• Last Update Submitted That Met QC Criteria: October 19, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: SPH3348-102

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No